New RNA shot directly into tumors could boost immune attack
NCT ID NCT06249048
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new drug called STX-001, a self-replicating RNA that makes a protein to stimulate the immune system. It is injected directly into tumors, either alone or with the immunotherapy pembrolizumab (Keytruda). The study aims to find a safe dose and see if it can shrink advanced solid tumors in about 108 adults.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
STX-001 (a self-replicating RNA that produces IL-12, injected directly into tumors) and pembrolizumab (Keytruda, an immunotherapy drug)
What this could lead to
If it works, this could offer a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This is an early first-in-human trial, so safety and effectiveness are not yet known. The treatment may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cleveland Clinic
NOT_YET_RECRUITINGCleveland, Ohio, 44195, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
HonorHealth Research and Innovation Institute
NOT_YET_RECRUITINGScottsdale, Arizona, 85258, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Huntsman Cancer Institute - University of Utah
NOT_YET_RECRUITINGSalt Lake City, Utah, 84112, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Melanoma Institute Australia
RECRUITINGWollstonecraft, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NextGen Oncology
RECRUITINGBeverly Hills, California, 90212, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Pittsburgh Medical Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••